Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer

The onset of brain metastases (BM) is a major turning point during advanced breast cancer (ABC) evolution, with only few treatment options when local therapies have failed. The therapeutic effect of eribulin, a wildly used drug in the treatment of ABC, remains unclear in this setting. We performed a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2021-03, Vol.10 (6), p.1272
Main Authors: Sabatier, Renaud, Martin, Johan, Vicier, Cécile, Guérin, Mathilde, Monneur, Audrey, Provansal, Magali, Tassy, Louis, Tarpin, Carole, Extra, Jean-Marc, Viret, Frédéric, Goncalves, Anthony
Format: Article
Language:English
Subjects:
Blood-brain barrier
Brain cancer
Breast cancer
Cancer
Cancer therapies
Clinical medicine
Data collection
Life Sciences
Medical prognosis
Metastasis
Neurosurgery
Patients
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The onset of brain metastases (BM) is a major turning point during advanced breast cancer (ABC) evolution, with only few treatment options when local therapies have failed. The therapeutic effect of eribulin, a wildly used drug in the treatment of ABC, remains unclear in this setting. We performed a retrospective observational study to assess eribulin efficacy in patients with ABC who displayed BM at time of eribulin initiation. We collected data from the medical files of all ABC patients who received eribulin at our institution from 2012 until 2020. Our main endpoint was the central nervous system (CNS) progression-free survival. (CNS-PFS). Other evaluation criteria were extra-cranial progression free survival (PFS) and overall survival (OS). Twenty patients with BM monitoring data available were selected out of the 549 who received eribulin during the inclusion period. Fifteen patients (75%) had BM progressive as the best response, three patients (15%) had disease stabilization for more than 6 months and only one patient had a partial response according to RECIST 1.1 criteria. Median CNS-PFS was 3.39 months (95CI (3.02-3.76)). Cox univariate analysis identified molecular subtype as the only prognostic parameter in our cohort, with patients with hormone-receptor positive tumors less likely to experience CNS progression than those with triple-negative MBC (HR = 0.23 (95CI = 0.07-0.80), = 0.021). Median extra-cranial PFS was 2.67 months (95CI (2.33-3.01)). Median OS was 7.68 months (95CI (0-17.41)). Eribulin seems to have only a limited impact on BM evolution. Hormone receptors expression may identify a subset of patients with better BM control.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm10061272